Plunkett Research Online: Resverlogix Corp

RESVERLOGIX CORP (RVX:TSE) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Resverlogix Corp is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. It is developing RVX-208, a small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds aris.....



Resverlogix Corp
Ticker: RVX
Exchange: TSE
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 403 254-9252
Fax: 1 403 256-8495
Address: 4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
ContactsDescription
Donald McCaffreyCEO/Co-Founder/Director/President/Secretary/Chairman of the Board
A. CannCFO
See More
Resverlogix Corp is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. It is developing RVX-208, a small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds aris.....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: